Novartis Challenge To Another India Gleevec Patent Request Comes To Light (India)
This article was originally published in PharmAsia News
Novartis has filed another challenge to India's patent rejections, this time for a second version of its Gleevec (imatinib mesylate) drug to fight blood cancer. An opposition filing by Indian company Okasa brought to light an apparent 2004 challenge by Novartis for rejection of its alpha crystal form of the drug. Okasa's attorney called the Novartis filing for the alpha version, already available in generic form by India's Cipla, "yet another frivolous patenting attempt" by the Swiss firm. The Chennai patent office had scheduled two hearings on the Okasa filing, but Novartis asked for adjournments in both cases, the lawyer said. A Novartis application for a patent on a beta version also was rejected by the Chennai patent office. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.